Royalty Pharma PLC $RPRX is Regal Partners Ltd’s 10th Largest Position

Regal Partners Ltd raised its position in Royalty Pharma PLC (NASDAQ:RPRX) by 6.7% in the 3rd quarter, Holdings Channel reports. The fund owned 1,435,126 shares of the biopharmaceutical company’s stock after acquiring an additional 89,930 shares during the period. Royalty Pharma accounts for approximately 3.6% of Regal Partners Ltd’s holdings, making the stock its 10th biggest position. Regal Partners Ltd’s holdings in Royalty Pharma were worth $50,631,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. CWM LLC raised its holdings in Royalty Pharma by 1.5% during the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 281 shares in the last quarter. GAMMA Investing LLC lifted its position in Royalty Pharma by 9.6% in the third quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 289 shares during the period. Merit Financial Group LLC boosted its holdings in Royalty Pharma by 3.5% in the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 306 shares in the last quarter. Wedmont Private Capital increased its position in Royalty Pharma by 5.1% during the 3rd quarter. Wedmont Private Capital now owns 6,793 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 331 shares during the period. Finally, Xponance Inc. increased its position in Royalty Pharma by 0.8% during the 3rd quarter. Xponance Inc. now owns 41,254 shares of the biopharmaceutical company’s stock worth $1,455,000 after purchasing an additional 331 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

RPRX stock opened at $45.41 on Friday. The firm has a 50 day moving average of $42.54 and a 200-day moving average of $39.22. The company has a market cap of $26.20 billion, a price-to-earnings ratio of 33.64 and a beta of 0.40. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a 12-month low of $29.66 and a 12-month high of $47.86.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The business had revenue of $621.99 million for the quarter, compared to analysts’ expectations of $839.97 million. As a group, equities analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be given a dividend of $0.235 per share. The ex-dividend date is Friday, February 20th. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 dividend on an annualized basis and a yield of 2.1%. Royalty Pharma’s dividend payout ratio (DPR) is presently 69.63%.

Analyst Ratings Changes

RPRX has been the subject of several recent analyst reports. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Weiss Ratings raised Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, February 12th. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Morgan Stanley reissued an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a report on Thursday, February 12th. Finally, Leerink Partners set a $45.00 target price on shares of Royalty Pharma in a research report on Thursday, December 11th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $48.67.

Insider Buying and Selling at Royalty Pharma

In other news, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $46.78, for a total transaction of $1,627,522.98. Following the completion of the transaction, the chief financial officer owned 45,761 shares of the company’s stock, valued at $2,140,699.58. The trade was a 43.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $41.09, for a total transaction of $821,800.00. The SEC filing for this sale provides additional information. Insiders sold 737,078 shares of company stock worth $29,862,002 in the last three months. 18.90% of the stock is owned by corporate insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.